Analyst firms · UBS · ZBH

UBS ZBH price target and rating history

Zimmer Biomet Holdings Inc. (ZBH) · Health Care

UBS rates Zimmer Biomet Holdings Inc. (ZBH) Buy with a $115 price target, as of its latest action on Jul 28, 2026. It has published 4 rating actions on ZBH since February 2022, including 0 upgrades and 1 downgrade. Across 6 firms with a ZBH price target in the last 12 months, the median target is $100. UBS's $115 is 15% above that.

Current rating

Buy

Price target

$115

Median target, all firms

$100

Actions on ZBH

4

UBS price target on ZBH

Every UBS rating on ZBH

• Jul 28, 2026
  InitiateUBS starts coverage at Buy, price target $115
• Mar 29, 2023
  InitiateUBS starts coverage at Sell, price target $112
• Feb 8, 2022
  ReiterateUBS cuts its price target to $121 from $130, keeps Neutral
• Feb 2, 2022
  DowngradeUBS downgrades to Neutral from Buy, price target $172 to $130

How other firms rate ZBH

Each firm's latest rating and stated target in the last 12 months.

Questions about UBS and ZBH

What is UBS's price target for ZBH?

UBS's latest stated price target for Zimmer Biomet Holdings Inc. (ZBH) is $115, from its action on Jul 28, 2026.

What is UBS's rating on ZBH?

UBS rates ZBH Buy, a bullish rating, as of Jul 28, 2026.

When did UBS last change its view on ZBH?

On Jul 28, 2026, UBS starts coverage at Buy, price target $115.

How does UBS's ZBH target compare with other analysts?

Across 6 firms with a ZBH price target in the last 12 months, the median target is $100. UBS's $115 is 15% above that.

More ZBH rating histories

• Barclays3
• BTIG3
• Raymond James3
• Evercore ISI4
• Piper Sandler3
• Jefferies3
• RBC Capital Markets3
• Wells Fargo3
• Needham4
• Truist Securities3
• Loop Capital3

All UBS ratingsZBH news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.